(NEPH) Nephros - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6406714005

NEPH: Ultrafiltration Products, Water Filters, Filtration Systems, Water Purifiers

Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey. Web URL: https://www.nephros.com

Additional Sources for NEPH Stock

NEPH Stock Overview

Market Cap in USD 16m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC Sub-Industry Household Appliances
IPO / Inception 2004-09-21

NEPH Stock Ratings

Growth 5y -89.5%
Fundamental -18.1%
Dividend -
Rel. Strength Industry -265
Analysts 4.5/5
Fair Price Momentum 1.05 USD
Fair Price DCF 1.85 USD

NEPH Dividends

No Dividends Paid

NEPH Growth Ratios

Growth Correlation 3m 33.5%
Growth Correlation 12m -90.2%
Growth Correlation 5y -69.8%
CAGR 5y -30.41%
CAGR/Mean DD 5y -0.53
Sharpe Ratio 12m -1.73
Alpha -76.58
Beta 0.75
Volatility 91.23%
Current Volume 32.3k
Average Volume 20d 10.2k
What is the price of NEPH stocks?
As of January 22, 2025, the stock is trading at USD 1.57 with a total of 32,254 shares traded.
Over the past week, the price has changed by +4.67%, over one month by +5.72%, over three months by +9.03% and over the past year by -55.77%.
Is Nephros a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Nephros is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -18.10 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NEPH as of January 2025 is 1.05. This means that NEPH is currently overvalued and has a potential downside of -33.12%.
Is NEPH a buy, sell or hold?
Nephros has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy NEPH.
  • Strong Buy: 1
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for NEPH stock price target?
According to ValueRays Forecast Model, NEPH Nephros will be worth about 1.2 in January 2026. The stock is currently trading at 1.57. This means that the stock has a potential downside of -26.75%.
Issuer Forecast Upside
Wallstreet Target Price 4.8 202.5%
Analysts Target Price 4.8 202.5%
ValueRay Target Price 1.2 -26.8%